Lesson 1 - The Gluten-free Diet: What can Patients with Celiac Disease Eat?
Optional further reading: Mechanisms for potential future therapies
Although proven to be effective for the treatment of CeD, the gluten-free diet brings along social, financial and medical challenges. Therefore, physicians are often asked about future therapies that may eventually replace the gluten-free diet. Because gluten is ubiquitously present, patients are often unintentionally exposed to gluten in amounts high enough or persistent enough to cause symptoms and even mucosal damage. As a consequence, gluten-related symptoms and incomplete mucosal healing are commonly seen.
An initial and realistic goal for the development of first-generation therapeutics is the neutralization of moderate amounts of gluten to protect patients from inadvertent or unavoidable gluten ingestion. They are therefore an adjunctive therapy to the gluten-free diet, not a replacement, and would let the patients consume at least small amounts of gluten without having to fear health consequences. The ultimate goal of drug development is to achieve immune tolerance, as it would practically mean a cure for CeD (Schuppan et al. 2009, Wungjiranirun et al. 2016).
Drug development is currently ongoing and the first phase III trials are in preparation.
IMPORTANT: The following therapeutic approaches are either just a theory or still under investigation. None of them has been approved or can be recommended for patients with CeD so far!
Figure 10 Ideas for other therapeutic approaches to treat CeD.
Source: Schuppan et al. 2009 (modified) figure 3, page 1922
Modified or pre-treated gluten
Different wheat varieties have different abilities to elicit an immune response. The major (hexaploid) utilized species is more toxic compared to less widely used (tetraploid) species. Breeding of wheat strains with reduced immunogenicity, obtained by selection from existing varieties or by genetic modification, may lead to gluten epitopes that are less toxic.
Immunogenicity can be modified by pretreating flours e.g. with certain lactobacilli that are added to sourdough for fermentation and that proteolyze proline/glutamine-rich peptides. Intrinsic proteases are produced during germination of the growing plant. Therefore, flour produced from germinating grains may lead to less toxic flours, which may however reduce baking quality. Although deamidation usually enhances immunogenicity, the immunogenic epitopes could also be inactivated through overdeamidation by microbial transglutaminases. The modified peptides may lose their affinity for HLA-DQ2 or abrogate the stimulatory effect on T-cells while even improving dough quality.
Glutenases
The high proline content of gluten makes it very resistant to digestive proteases. The large peptides are recognized by tTG (TG2), initiating the pathological cascade of CeD. Oral enzyme therapies e.g. prolyl endopeptidases can cleave proline-rich regions, thereby destroying immuno-dominant epitopes. This therapy is not aimed at degrading epitopes in normal gluten ingestion and this was shown by an in-vitro study showing that this strategy is only partly successful and not reliable to replace a gluten-free diet (Monserrat et al. 2015).
Gluten binders
Intraluminal binding of gluten peptides blocks gliadin digestion into smaller immunogenic peptides.
Oral gluten neutralization by cow's milk antibodies
Gluten could be neutralized by IgG antibodies derived from cow’s milk. They are highly resistant to gastric acidity. As they are considered a safe nutritional product, no regulatory approval is needed.
Permeability inhibitors (AT-1001)
Increased intestinal permeability via opening of epithelial tight junctions contributes to the influx of gluten into the lamina propria, where the T-cell response is triggered. Blocking the responsible receptors (zonulin receptors) of the tight junctions can protect the integrity of the tight junctions.
Lymphocyte blocking (anti-IL-15, anti-CCR9, anti-α4β7)
The chemokine CCR9 and the integrin α4β7 both play an important role in homing of leukocytes to the small intestine. Their specific role is still controversial in CeD. Anti-CCR9 and anti-α4β7 are currently studied primarily in other autoimmune diseases such as inflammatory bowel disease.
IL-15 plays a central role in CeD pathogenesis. Therefore, IL-15 antagonists or IL-15-blocking antibodies may be a potential therapy, especially in refractory CeD type 2 in which expansion of malignant lymphocytes seems to be driven by IL-15.
tTG (TG2)-inhibitors
Inhibiting gliadin
deamidation could reduce binding to HLA-DQ2/DQ8 and therefore T-cell
stimulation. Although potentially useful, it is risky as different
transglutaminases fulfill many important functions in the body.
DQ2-blocking peptide
analogues
Adaptive immunity is
driven by antigen presentation of HLA-DQ2 in the majority of patients. Agonists
binding to DQ2 without eliciting a subsequent T-cell response are currently
investigated. This approach requires significant work to produce highly
specific, high-affinity, non-toxic, non-immunogenic compounds before they can
be tested in humans.
Tolerance induction - gluten "immunization"
Tolerance induction has been attempted by intranasal administration of gliadin peptides in a specific CeD mouse-model. Another mouse-model has been “vaccinated” subcutaneously with immunogenic peptides. Both methods led to decreased T-cell proliferation and production of inflammatory cytokines and the vaccination strategy to an increased expression of Treg markers.
Tolerance induction - Hookworm inoculation
Administration of Bifidobacterium strains is investigated in terms of their potential to regulate the proinflammatory environment in the intestine of CeD patients. Larvae of the hookworm are studied in terms of their potential to skew the proinflammatory Th1 T-cell response to a less aggressive Th2 response or to a suppressive Treg response similar to the therapy with Trichuris suis in inflammatory bowel disease.